Harvard Apparatus Regenerative Technology Inc.
Harvard Apparatus Regenerative Technology Inc., a clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth defects. Its lead product candidate is Cellspan Esophageal Implant for the treatment of severe esophageal disease. The company's pipeline includes organ-… Read more
Harvard Apparatus Regenerative Technology Inc. (HRGN) - Total Liabilities
Latest total liabilities as of September 2025: $992.00K USD
Based on the latest financial reports, Harvard Apparatus Regenerative Technology Inc. (HRGN) has total liabilities worth $992.00K USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Harvard Apparatus Regenerative Technology Inc. - Total Liabilities Trend (2019–2024)
This chart illustrates how Harvard Apparatus Regenerative Technology Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Harvard Apparatus Regenerative Technology Inc. Competitors by Total Liabilities
The table below lists competitors of Harvard Apparatus Regenerative Technology Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jembo Cable Company Tbk
JK:JECC
|
Indonesia | Rp1.65 Trillion |
|
CU Medical Systems Inc
KQ:115480
|
Korea | ₩42.18 Billion |
|
GameSparcs Co Ltd
TWO:6542
|
Taiwan | NT$184.07 Million |
|
Roscan Gold Corp
OTCQB:RCGCF
|
USA | $2.84 Million |
|
Netgem S.A.
LSE:0N9W
|
UK | €23.70 Million |
|
Atende S.A.
WAR:ATD
|
Poland | zł171.45 Million |
|
ICTS International N.V
OTCQB:ICTSF
|
USA | $101.45 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Harvard Apparatus Regenerative Technology Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.64 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.39 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Harvard Apparatus Regenerative Technology Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Harvard Apparatus Regenerative Technology Inc. (2019–2024)
The table below shows the annual total liabilities of Harvard Apparatus Regenerative Technology Inc. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.22 Million | +26.03% |
| 2023-12-31 | $968.00K | -31.40% |
| 2022-12-31 | $1.41 Million | -71.17% |
| 2021-12-31 | $4.89 Million | +414.72% |
| 2020-12-31 | $951.00K | +5.32% |
| 2019-12-31 | $903.00K | -- |